Small cell lung cancer Trial of Olaparib (AZD2281) as Maintenance Programme: a randomised, double blind, multicentre phase II trial.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Mar 2016
At a glance
- Drugs Olaparib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Acronyms STOMP
- 11 Feb 2016 Accural to date is 100% as reported by United Kingdom Clinical Research Network.
- 11 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by United kingdom Clinical Research Network.
- 11 Feb 2016 Planned End Date changed from 19 Sep 2015 to 11 Dec 2015 as reported by United Kingdom Clinical Research Network.